Holen Sie sich die Stockscreener-App
1.41
9.62%
-0.15
Schlusskurs vom Vortag:
$1.56
Offen:
$1.6
24-Stunden-Volumen:
3.59M
Relative Volume:
3.04
Marktkapitalisierung:
$171.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.33M
KGV:
-4.9929
EPS:
-0.2824
Netto-Cashflow:
$-17.65M
1W Leistung:
-17.54%
1M Leistung:
-35.02%
6M Leistung:
+0.00%
1J Leistung:
+34.29%
1-Tages-Spanne:
$1.40
$1.64
1-Wochen-Bereich:
$1.40
$1.71
52-Wochen-Spanne:
$0.88
$2.34
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.41 | 207.79M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Discontinued operations of Cardiol Therapeutics Inc. Class A – HAN:CT9 - TradingView
Tejara Capital Ltd Expands Stake in Cardiol Therapeutics Inc (CR - GuruFocus
Can Cardiol Therapeutics (TSX:CRDL) Turn Research Into Progress? - kalkinemedia.com
Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early - the deep dive
Cardiol Therapeutics Inc. (CRDL.TO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics Inc. (CRDL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cardiol Therapeutics Slides Under Pressure: Clinical-Stage Uncertainty and Shelf Prospectus Overhang Weigh on Investor Sentiment - kalkine.ca
Cardiol Therapeutics Inc (CRDL) Stock Price Target & Forecast - TradingKey
Cardiol Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co. - Moomoo
Tejara Capital Holds 5.3% Stake in Cardiol Therapeutics (NASDAQ: CRDL), Owning 6.38 Million Shares - kalkinemedia.com
CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9.00 - GuruFocus
Fund manager reports 6.4M Cardiol Therapeutics (NASDAQ: CRDL) shares - Stock Titan
HC Wainwright & Co. reiterates Buy rating on Cardiol Therapeutics, $9 price target - TradingView
Cardiol expands phase III trial enrollment to 150 patients By Investing.com - Investing.com Nigeria
Cardiol Therapeutics (CRDL) Advances MAVERIC Phase III Trial, Ma - GuruFocus
Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone - TipRanks
Fewer relapses in heart trial push Cardiol Therapeutics (CRDL) to add patients and delay results - Stock Titan
Cardiol expands phase III trial enrollment to 150 patients - Investing.com India
Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead Of Schedule And Expands Pivotal Trial To Strengthen Assessment Of Cardiolrx's Efficacy - TradingView
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy - PR Newswire
Why Are Markets Watching Cardiol Therapeutics (TSX:CRDL) Midcap Shares? - kalkinemedia.com
Cardiol Therapeutics Inc. (TSX:CRDL): A Fresh Healthcare Stocks Catalyst Today - kalkinemedia.com
Cardiol Therapeutics Inc. (TSX:CRDL) Back In Focus For Growth Stocks Watchers - Kalkine Media
Cardiol Therapeutics Inc. (TSX:CRDL): Today's Cannabis Stocks Story - kalkinemedia.com
Cardiol Therapeutics (Nasdaq: CRDL) opens path to raise cash for heart drug trials - Stock Titan
Cardiol Therapeutics (CRDL) Raises $7M via Warrants, Extends Run - GuruFocus
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds - PR Newswire
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Declines 6.86% as Selling Pressure Builds - kalkine.ca
New conduct code at Cardiol Therapeutics (CRDL) tightens conflict, confidentiality and whistleblower rules - Stock Titan
WHY TerrAscend (TSX:TSND), Cardiol Therapeutics Inc. (TSX:CRDL), Vizsla Royalties (TSXV:VROY), Quarterhill (TSX:QTRH) and GoldMining (TSX:GOLD) Could Put the TSX SmallCap Watchlist in Focus in September 2026 - kalkine.ca
CRDL: Phase III data readout and expansion into heart failure set the stage for broad market impact - TradingView
Cardiol Therapeutics: Q1 2027 Readout Will Be Make-Or-Break For MAVERIC (NASDAQ:CRDL) - Seeking Alpha
CRDL: Cardiol Therapeutics IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Cardiol Therapeutics (TSX:CRDL) Slides 12.34% as Volatility Returns and Investors Reassess the Clinical-Stage Risk - kalkine.ca
Cardiol Therapeutics Stock Faces Renewed Pressure as Biotech Risk and Clinical Uncertainty Weigh on Sentiment - kalkine.ca
Cardiol Therapeutics (CRDL) sets terms with new manufacturing and drug ingredient partners - Stock Titan
Cardiol Therapeutics files $150 million shelf prospectus By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus - TradingView
Cardiol Therapeutics files $150 million shelf prospectus - investing.com
New 25‑month shelf lets Cardiol Therapeutics (CRDL) line up future financing - Stock Titan
Cardiol Therapeutics files US$150M base shelf prospectus - tradingview.com
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission - PR Newswire
Cardiol Therapeutics Inc. (NASDAQ: CRDL) to Host Fireside Chat on September 14 at H.C. Wainwright Investment Conference - kalkinemedia.com
Cardiol Therapeutics (NASDAQ: CRDL) lines up new shelf to fund drug trials - Stock Titan
Cardiol Therapeutics Files For Mixed Shelf Offering Of Up To $150 Mln - tradingview.com
Cardiol Therapeutics Inc. Class A (TSX:CRDL) Gains Momentum as Cardiovascular Drug Pipeline Progress Strengthens Investor Optimism - kalkine.ca
Cardiol Therapeutics (TSX:CRDL) Healthcare Stock Latest Update - Kalkine Media
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Heart-drug developer Cardiol Therapeutics (CRDL) heads to a major New York investor conference - Stock Titan
Cardiol Therapeutics will join a heart-disease drug chat in New York Sept. 14 - Stock Titan
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
5.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):